Biotech

All Articles

Neurocrine's KarXT competitor hits in phase 2-- but only at reduced dose

.Neurocrine Biosciences has actually obtained its hoped-for account in a stage 2 mental illness test...

Vaderis' rare blood vessel problem medicine lessens nosebleeds

.Vaderis Therapeutics' objective to build the very first medicine targeted exclusively at a certain ...

Navigator rears $100M to establish brand new autoimmune pipeline

.Sat nav Medicines has furnished on its own with $one hundred thousand in set A funds as the younger...

Duality finds cash for ADC trials as IPO surge spreads to Asia

.China's Duplicity Biotherapeutics has filed (PDF) paperwork for a Hong Kong IPO, seeking a confiden...

YolTech offers China liberties to genetics editing therapy for $29M

.4 months after Mandarin genetics modifying firm YolTech Rehabs took its own cholesterol disease-foc...

Addex stock rises after Indivior provides to $300M for material

.Indivior is getting a tiny particle allosteric modulator tailored to handle substance usage problem...

Molecular Partners fine-tunes AML trial over 'suboptimal visibility'

.Molecular Partners has determined "suboptimal direct exposure" to its tetra-specific T-cell engager...

Despite blended market, a venture capital revival may be can be found in Europe: PitchBook

.While the biotech investment scene in Europe has actually reduced somewhat complying with a COVID-1...

8 months after a $213M fundraise, gene editor Volume produces cuts

.After raising $213 thousand in 2023-- some of the year's largest private biotech rounds-- Tome Bios...

BioMarin develops director staff along with biotech veterinarians-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings ...